Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

PURPOSE: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, ide...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Main Authors: Lin, Ling, Wu, Xiaomai, Yan, Shuangquan, Zhu, Yefei, Yan, Zhengqing, Lv, Dongqing, Ge, Hongfei
Formato: Artigo
Idioma:Inglês
Publicado: Dove 2020
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7533245/
https://ncbi.nlm.nih.gov/pubmed/33061454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S268694
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares